Clinical Trial: A Study of CLEC2A CAR T for Pediatric and Adult Patients With Relapsed or Refractory AML

U.S., Oct. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07905027) titled 'A Study of CLEC2A CAR T for Pediatric and Adult Patients With Relapsed or Refractory AML' on Sept. 22.

Brief Summary: This is a phase I, open-label, non-randomized clinical trial that will enroll pediatric and adult research participants with CLEC2A+ acute myeloid leukemia (AML) that does not go away with treatment (is refractory) or comes back after treatment (is recurrent). The goal is to evaluate the safety, feasibility, and efficacy of administering T cell products (modified immune cells) derived from the research participant's blood that have been genetically modified to express chimeric antigen receptor (CAR) targeting SC-CAR....